ETHK Labs stock has drifted over the past week while the latest earnings land with a much sharper message. The headline is not revenue; it is the profit squeeze. Management reported H1 2026 total revenue of C¥1,353.7m, yet the company swung to a net loss of C¥70.5m with basic earnings per share of C¥0.0439 loss. For a healthcare stock already trading on a low 0.3x trailing P/S ratio, that widening loss is what really tests investor conviction today.
Is ETHK Labs trading at a genuine bargain multiple or signalling deeper earnings risk? Compare its low 0.3x P/S against peers using the valuation analysis for ETHK Labs
H1 2026 Earnings Summary
- Revenue (H1 2026 vs H1 2025): C¥1,353.7m vs. C¥1,269.6m (higher revenue year on year)
- Net Income or Loss (H1 2026 vs H1 2025): loss of C¥70.5m vs. profit of C¥39.1m (moved from profit to loss)
- Basic EPS (H1 2026 vs H1 2025): loss of C¥0.0439 per share vs. earnings of C¥0.0241 per share (earnings per share moved from profit to loss)
- Trailing 12 Month Net Income or Loss (TTM to H1 2026 vs TTM to H1 2025): loss of C¥74.7m vs. profit of C¥174.3m (profitability shifted to a loss over the trailing year)
Prefer clear visual charts instead of another wall of earnings figures and ratios? See ETHK Labs' recent profit squeeze and revenue trend presented in an at-a-glance visual format through the full company report for ETHK Labs.
ETHK Labs revenue resilience versus profit pressure
For investors leaning positive on ETHK Labs, the latest figures offer only partial support. Revenue of C¥1,353.7m in H1 2026 sits above the prior C¥1,269.6m, which fits a healthcare diagnostics story where demand can be steady. However, the swing from a C¥39.1m profit in H1 2025 to a C¥70.5m loss in H1 2026, and a trailing twelve month loss of C¥74.7m, shows the integrated model is currently not translating into earnings strength.
Profit squeeze reinforces near term risk concerns
The bearish angle on ETHK Labs finds stronger backing in these results. The move from profit to loss at both half year and trailing twelve month level suggests cost or pricing pressure is biting. The stock has declined about 6% over 7 days and 17.6% over 90 days to HK$0.585 as at 1 September 2026. That reaction indicates the market is treating the profit squeeze as more than a temporary bump.
After a 16% annual earnings decline over 5 years and recent share price swings, review our independent risk analysis for ETHK Labs which shows 2 important warning signsTake Control Of Your Next Move
If ETHK Labs looks worth tracking after its recent profit squeeze and share price pullback, register for free with Simply Wall St and add it to your Watchlist to watch how the price lines up against fair value and wait for a better entry point. Once you hold the stock, use the Portfolio Command Center to cut through noise and receive only the key developments that matter for your decisions. Over the longer run, tap into the Community to see how other investors are interpreting the same data and earnings signals. By surfacing potential catalysts and risks early, Simply Wall St helps you stay ahead of market moves and act with more confidence.
Curious About Alternative Stock Paths
Fresh ideas do not stay under the radar for long. Some stocks build quiet momentum while others are caught dropping before the crowd reacts. Check these themes now and explore them early.
- Spot strong cash generators before momentum potentially picks up by scanning a curated set of 262 high quality undervalued stocks while the valuations still look compelling.
- Follow the growth of real-world applications in automation and smart factories by focusing on carefully filtered 38 robotics and automation stocks that could attract market attention.
- Review focused 39 power grid technology and infrastructure stocks to consider possible infrastructure and demand tailwinds that some investors may not have fully priced in.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com